Curemark is a biopharmaceutical company focused on developing therapies for the treatment of neurological and other disorders. Its pipeline includes preclinical and clinical-stage programs for patients with autism, ADHD (attention deficit hyperactivity disorder), addiction, schizophrenia, and Parkinson’s disease.